Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574021 | 0.82 | TRPA1 (0.36) | — | |
| SCHEMBL2261460 | 0.82 | PGK1 (0.42) | PGK1PGK2 | |
| SCHEMBL502038 | 0.82 | ALDH1A1 (0.40) | TACR1PGK1PGK2 | |
| SCHEMBL4160774 | 0.79 | ALDH1A1 (0.38) | TACR1PGK1PGK2 | |
| SCHEMBL16959454 | 0.78 | PTGS2 (0.33) | TACR1PGK1PGK2 | |
| SCHEMBL21768252 | 0.76 | TACR1 (0.31) | TACR1PGK1PGK2 | |
| SCHEMBL30831854 | 0.76 | TACR1 (0.31) | TACR1PGK1PGK2 | |
| SCHEMBL8364823 | 0.76 | TAAR1 (0.34) | TACR1PGK1PGK2 | |
| SCHEMBL16957404 | 0.76 | ACHE (0.39) | TACR1PGK1PGK2 | |
| SCHEMBL26586433 | 0.76 | TACR1 (0.31) | TACR1PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119800-B2 | Processes for preparing HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-02-21 | — | — | US | disclosed |
| WO-2009085797-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | TACR1 2100/4885PGK1 2122/4885PGK2 2004/4885 |
| US-20090163712-A1 | PROCESSES FOR PREPARING HIV REVERSE TRANSCRIPTASE INHIBITORS | POLB, POLR2E, POLR2H | TACR1 3179/4885PGK1 304/4885PGK2 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.